| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 29 Jul 2025 | 23 Jul 2025 |
| Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/07/2025 inter alia to consider and approve the unaudited standalone and consolidated financial results of the Company for the quarter ended June 30 2025 Approval of unaudited financial results Re-appointment of Internal Auditors (As per BSE Announcement Dated on 29/07/2025) | ||
| Board Meeting | 12 Jun 2025 | 12 Jun 2025 |
| Disclosure under Regulation 30 - Sale and Transfer of API Business of the Company on Slump Sale basis to Jubilant Biosys Limited, a wholly owned subsidiary company | ||
| Board Meeting | 16 May 2025 | 30 Apr 2025 |
| Audited Results & Final Dividend Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2025 ,inter alia, to consider and approve 1. The audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2025. 2. Recommendation of Final Dividend, if any, for the Financial Year ended March 31, 2025. Board Meeting Outcome for Outcome Of Board Meeting Held On May 16 2025 Appointment of Secretarial Auditors (As Per BSE Announcement Dated on: 16/05/2025) | ||
| Board Meeting | 31 Jan 2025 | 23 Jan 2025 |
| Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 31/01/2025 ,inter alia, to consider and approve Unaudited Standalone and Consolidated Financial Results of the Company for the quarter and nine months ended December 31, 2024. Re Outcome of Board Meeting (As Per BSE Announcement Dated on 31/01/2025) | ||
| Board Meeting | 25 Oct 2024 | 17 Oct 2024 |
| Jubilant Pharmova Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/10/2024 inter alia to consider and approve Intimation of Board Meeting - To consider the unaudited Financial Results for the Quarter and Half Year ended September 30 2024. Outcome of the Board Meeting held on October 25, 2024 - Approval of Unaudited Financial Results for quarter and half year ended September 30, 2024 Approval of Unaudted Financial Results for the quarter and half year ended September 30, 2024 (As Per BSE Announcement Dated on 25.10.2024) | ||
The API division posted a turnover of ₹609 Crore for the financial year ended March 2025. This was 8.35% of the company’s consolidated revenue.
Here are some of the stocks that may see significant price movement today: Torrent Power, DCM Shriram, Jubilant Pharmova, etc.
This FDA audit confirms compliance with regulatory standards, enhancing the credibility of Jubilant's operations in the United States.
Jubilant Pharmova Ltd has gained a total of 126% in the last one year, and almost 75% gain since the beginning of the year.
Here are some of the stocks that may see significant price movement today: Tata Motors, Reliance Industries, IREDA, etc.
Drug company Jubilant Pharmova Ltd will acquire an 80% stake in Pierre Fabre Laboratories' Research & Development Centre in Saint Julien, France.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
